Nrc Health Revenue Growth Rates (NRC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nrc Health  (NASDAQ: NRC)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

NRC's Revenue Growth by Quarter and Year

Nrc Health's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NRC/growth
https://api.csimarket.com/api/v1/companies/NRC/fundamentals
https://api.csimarket.com/api/v1/companies/NRC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NRC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 38.40
2nd Quarter June 35.39
1st Quarter March 34.80
FY 108.59

NRCs Annual Revenue
Nrc Health's Revenue in the fiscal year 2025 $ 137.39 millions
Nrc Health's Revenue in the fiscal year 2024 $ 143.06 millions
Nrc Health's Revenue in the fiscal year 2023 $ 148.58 millions
Nrc Health's Revenue in the fiscal year 2022 $ 151.57 millions
Nrc Health's Revenue in the fiscal year 2021 $ 147.95 millions




NRC Revenue third quarter 2026 Y/Y Growth Comment
Nrc Health achieved in the third quarter 2026, above Company average Revenue increase of 10.95% year on year, to $ 38.40 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 21 other companies have achieved higher Revenue growth. While Nrc Health' s Revenue growth of 10.95% ranks overall at the positon no. 2372 in the third quarter 2026.


NRC Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.95 %
2nd Quarter June 3.97 %
1st Quarter March 3.73 %
FY   -

Financial Statements
Nrc Health's third quarter 2026 Revenue $ 38.40 millions NRC's Income Statement
Nrc Health's third quarter 2025 Revenue $ 34.61 millions Quarterly NRC's Income Statement


NRC Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.5 %
2nd Quarter June 1.7 %
1st Quarter March -1.11 %
FY (Year on Year)   -


Back to NRC Growth rate Comparisons >> Back to NRC Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #343
Overall #2372

Revenue Y/Y Growth Statistics
High Average Low
29.54 % 5.08 % -5.6 %
(Mar 31 2017)   (Dec 31 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #343
Overall #2372
Revenue Y/Y Growth Statistics
High Average Low
29.54 % 5.08 % -5.6 %
(Mar 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nrc Health's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
17.25 % 1.3 % -10.25 %
(Mar 31 2012)  


NRC's III. Quarter Q/Q Revenue Comment
Nrc Health achieved in the III. Quarter 2026 above company average sequential Revenue increase of 8.5%, to $ 38.40 millions, from $35.39 millions in the second quarter.
NRC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Nrc Health's Revenue growth quarter on quarter, overall rank is 1542.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #211
Overall #1542
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #211
Overall #1542
Revenue Q/Q Growth Statistics
High Average Low
17.25 % 1.3 % -10.25 %
(Mar 31 2012)  


NRC's III. Quarter Q/Q Revenue Comment
Nrc Health achieved in the III. Quarter 2026 above company average sequential Revenue increase of 8.5%, to $ 38.40 millions, from $35.39 millions in the second quarter.
NRC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Nrc Health's Revenue growth quarter on quarter, overall rank is 1542.


Nrc Health's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 140.00
Y / Y Revenue Growth (TTM) -0.23 %
Year on Year Revenue Growth Overall Ranking # 2804
Seqeuential Revenue Change (TTM) 0.98 %
Seq. Revenue Growth (TTM) Overall Ranking # 2581


Cumulative Revenue growth Comment
Nrc Health showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Nrc Health's annual Revenue improvement would be -0.23% year on year to $140 millions.

In the Healthcare sector 394 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2119 to 2804.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 395
Overall # 2804

Revenue TTM Y/Y Growth Statistics
High Average Low
125.52 %
 8.12 %
-48.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 371
S&P 500 # 2581
Cumulative Revenue growth Comment
Nrc Health showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Nrc Health's annual Revenue drop would be -0.23% year on year to $140 millions.

In the Healthcare sector 394 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2119 to 2804.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 395
Overall # 2804

Revenue TTM Y/Y Growth Statistics
High Average Low
125.52 %
8.12 %
-48.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 371
S&P 500 # 2581




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NRC's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions


About Nrc Health Revenue Growth Rates (NRC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nrc Health (CIK 70487).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-034887
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nrc Health’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.